NO963589D0 - Beskrivelse av kreftilstander ved MAGE-genuttrykking - Google Patents
Beskrivelse av kreftilstander ved MAGE-genuttrykkingInfo
- Publication number
- NO963589D0 NO963589D0 NO963589A NO963589A NO963589D0 NO 963589 D0 NO963589 D0 NO 963589D0 NO 963589 A NO963589 A NO 963589A NO 963589 A NO963589 A NO 963589A NO 963589 D0 NO963589 D0 NO 963589D0
- Authority
- NO
- Norway
- Prior art keywords
- description
- gene expression
- mage gene
- cancer states
- mage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/204,727 US5512437A (en) | 1994-03-01 | 1994-03-01 | Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3 |
| US08/209,172 US5763165A (en) | 1994-03-10 | 1994-03-10 | Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 |
| US08/299,849 US5612201A (en) | 1991-05-23 | 1994-09-01 | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
| US08/346,774 US5512444A (en) | 1994-03-01 | 1994-11-30 | Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4 |
| PCT/US1995/002203 WO1995023874A1 (en) | 1994-03-01 | 1995-02-23 | Determination of cancerous conditions by mage gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO963589D0 true NO963589D0 (no) | 1996-08-28 |
| NO963589L NO963589L (no) | 1996-10-31 |
Family
ID=27498545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO963589A NO963589L (no) | 1994-03-01 | 1996-08-28 | Beskrivelse av kreftilstander ved MAGE-genuttrykking |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0871765B1 (no) |
| JP (1) | JPH09509832A (no) |
| KR (1) | KR100316209B1 (no) |
| AT (1) | ATE209690T1 (no) |
| AU (1) | AU698310B2 (no) |
| CA (1) | CA2184482A1 (no) |
| DE (1) | DE69524264T2 (no) |
| FI (1) | FI963393L (no) |
| NO (1) | NO963589L (no) |
| NZ (1) | NZ282536A (no) |
| WO (1) | WO1995023874A1 (no) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221593B1 (en) * | 1996-10-03 | 2001-04-24 | Ludwig Institute For Cancer Research | Method for determining cancer by determining expression of MAGE-10 |
| US5908778A (en) | 1996-10-03 | 1999-06-01 | Ludwig Institute For Cancer Research | Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof |
| CA2285688A1 (en) | 1997-04-11 | 1998-10-22 | Peter Kufer | Novel primers and methods for the detection of disseminated tumor cells |
| US6027924A (en) * | 1997-04-25 | 2000-02-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof |
| WO1999004265A2 (en) * | 1997-07-17 | 1999-01-28 | Ludwig Institute For Cancer Research | Cancer associated nucleic acids and polypeptides |
| CA2319309C (en) | 1998-02-05 | 2010-08-10 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
| US6686147B1 (en) | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
| EP1108025A2 (en) * | 1998-08-31 | 2001-06-20 | Urogenesys, Inc. | Phelix: a testis-specific protein expressed in cancer |
| US6733998B1 (en) * | 1998-12-07 | 2004-05-11 | Sloan-Kettering Institute For Cancer Research | Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto |
| US6475794B1 (en) * | 1999-10-08 | 2002-11-05 | The Johns Hopkins University | Converting diploidy to haploidy for genetic diagnosis |
| ATE527375T1 (de) | 2001-04-12 | 2011-10-15 | Imp Innovations Ltd | Diagnose und behandlung von brustkrebs mit scn5a |
| GB0612342D0 (en) * | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
| GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
| WO2016094309A1 (en) | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
| US10682390B2 (en) | 2015-07-16 | 2020-06-16 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| AU2018205888B2 (en) | 2017-01-05 | 2021-09-02 | Kahr Medical Ltd. | A PD1-41BBL fusion protein and methods of use thereof |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
| US20210187023A1 (en) | 2017-06-27 | 2021-06-24 | The Trustees Of Princeton University | Compositions And Methods For Enhancing Immunotherapy |
| GB201713078D0 (en) | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| AU2019211121B2 (en) | 2018-01-26 | 2024-09-12 | Cambridge Enterprise Limited | Peptide exchange protein |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| US12329816B2 (en) | 2018-08-24 | 2025-06-17 | The Trustees Of Princeton University | Immunotherapy with metabolic enzyme expression |
| GB201820444D0 (en) | 2018-12-14 | 2019-01-30 | Adaptimmune Ltd | Marker for T cell expansion |
| EP3997114A1 (en) | 2019-07-11 | 2022-05-18 | KAHR Medical Ltd. | Heterodimers and methods of use thereof |
| GB201911954D0 (en) | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Lentiviral transduction methods |
| US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
| WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| KR20230126727A (ko) | 2020-12-30 | 2023-08-30 | 이뮤노믹 쎄라퓨틱스, 인크. | 항-hvem 항체 |
| GB202303250D0 (en) | 2023-03-06 | 2023-04-19 | King S College London | Method and compounds |
| WO2025155971A1 (en) | 2024-01-19 | 2025-07-24 | Immunomic Therapeutics, Inc | Anti-activin receptor 1c (alk-7) receptor antibodies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
-
1995
- 1995-02-23 DE DE69524264T patent/DE69524264T2/de not_active Expired - Lifetime
- 1995-02-23 JP JP7522934A patent/JPH09509832A/ja not_active Ceased
- 1995-02-23 NZ NZ282536A patent/NZ282536A/en unknown
- 1995-02-23 WO PCT/US1995/002203 patent/WO1995023874A1/en not_active Ceased
- 1995-02-23 EP EP95912584A patent/EP0871765B1/en not_active Expired - Lifetime
- 1995-02-23 FI FI963393A patent/FI963393L/fi unknown
- 1995-02-23 AT AT95912584T patent/ATE209690T1/de active
- 1995-02-23 AU AU19682/95A patent/AU698310B2/en not_active Ceased
- 1995-02-23 CA CA002184482A patent/CA2184482A1/en not_active Abandoned
- 1995-02-23 KR KR1019960704814A patent/KR100316209B1/ko not_active Expired - Fee Related
-
1996
- 1996-08-28 NO NO963589A patent/NO963589L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0871765A1 (en) | 1998-10-21 |
| AU698310B2 (en) | 1998-10-29 |
| NZ282536A (en) | 1998-07-28 |
| KR970701790A (ko) | 1997-04-12 |
| ATE209690T1 (de) | 2001-12-15 |
| EP0871765A4 (en) | 1999-08-11 |
| DE69524264D1 (de) | 2002-01-10 |
| AU1968295A (en) | 1995-09-18 |
| FI963393A0 (fi) | 1996-08-30 |
| NO963589L (no) | 1996-10-31 |
| EP0871765B1 (en) | 2001-11-28 |
| DE69524264T2 (de) | 2002-07-18 |
| JPH09509832A (ja) | 1997-10-07 |
| KR100316209B1 (ko) | 2002-06-26 |
| FI963393A7 (fi) | 1996-08-30 |
| CA2184482A1 (en) | 1995-09-08 |
| FI963393L (fi) | 1996-08-30 |
| WO1995023874A1 (en) | 1995-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO963589D0 (no) | Beskrivelse av kreftilstander ved MAGE-genuttrykking | |
| ATE258379T1 (de) | Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert | |
| FI960268L (fi) | Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä | |
| AU588542B2 (en) | Immunoassay for breast cancer employing monoclonal antibodies | |
| ATE327330T1 (de) | Rekombinante humanisierte antikörper gegen fb5 | |
| NO902696L (no) | Ny familie av modifiserte hoeyaffinitets-antistoff for kreftbehandling. | |
| NO821367L (no) | Fremgangsmaate ved fremstilling av slitebestandige, sammensatte materialer. | |
| DE69004300D1 (de) | Verfahren zur Herstellung wellenförmiger Imbiss-Chips. | |
| AU4897096A (en) | Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen | |
| DE3586216D1 (de) | Brusttumorassoziiertes antigen und monoklonale antikoerper dazu. | |
| NO892068L (no) | Fremgangsmaate ved fremstilling av naftatiozepinoner. | |
| NO970030L (no) | Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 | |
| IT1226719B (it) | Metodo per produrre fluororesina tenera polimerizzata ad innesto. | |
| EP1072272A4 (en) | METHOD FOR OBTAINING A SPECIFIC ANTISERUM AGAINST THE UNIVERSAL TUMOR ANTIGEN AND METHOD FOR DIAGNOSING MALIGNANT TUMORS USING THE SAME | |
| FR2714915B1 (fr) | Fragment de gène, etc, d'un anticorps reconnaissant une mucine spécifique de cancers . | |
| AU5246190A (en) | Retinoblastoma gene product antibodies and uses therefor | |
| FR2731701B1 (fr) | Procede de fabrication de fluoroalcanes | |
| FI961723A7 (fi) | Uusi eturauhas/paksunsuolikasvaimen suppressorigeeni | |
| EP0614853A3 (en) | Method of making beta zeolite. | |
| FR2720277B1 (fr) | Méthode de traitement des cancers par régulation de la protéine P53. | |
| AU4403096A (en) | Method of diagnosing presence of malignant tumour | |
| AU2169797A (en) | Improved production of antibodies through the use of antigen antibody complexes | |
| WO1997010258A3 (de) | Antikörper gegen an oberflächen von carcinom-zellen ausserhalb von desmosomen exponierte epitope desmosomaler cadherine | |
| TR199501210A2 (tr) | Deri yaglama maddelerinin üretilmesine mahsus usul. | |
| IT1284797B1 (it) | Procedimento per la produzione di composti di pirazina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |